Moleculent Raises $20M Funding To Scale Cell Communication Mapping Technology

The round was led by Rubicon Healthcare Partners, with participation from ARCH Venture Partners, Eir Ventures, and existing investors.

The company plans to use the funding to expand its operations accelerate its commercial presence in the United States, and support the launch of its platform.

Led by CEO Olle Ericsson, Moleculent is developing a new approach called functional profiling, which maps how cells interact within intact tissue.

Its technology enables large-scale measurement of cell-to-cell interactions, offering researchers deeper insights into human biology and disease mechanisms.

Read Also - Featherless.ai Raises $20M To Grow Serverless Platform For Open-Source AI

The platform is currently available to academic and biopharma partners through Techstart, the company’s early access program.

“The market is telling us it’s ready,” said Olle Ericsson, PhD, Co-Founder and CEO of Moleculent. “We are seeing surging demand from leading research institutions and pharmaceutical partners across both Europe and the US. With Rubicon joining ARCH and Eir Ventures, we now have a syndicate of builders with successful track records of scaling life science companies from breakthrough technology to global impact. This new funding allows us to move moreaggressively as we work to put this platform into the hands of the scientists decoding the cellular conversations that drive human disease.”

About Moleculent

Moleculent is a life sciences company developing technology to study how cells communicate within human tissue. Its platform analyzes cell interactions in their natural environment, helping researchers understand healthy and diseased cells. This approach enables large scale functional proteomics offering deeper insights into human biology and disease mechanisms.